REFERENCES
1. Skill NJ, Butler J, O’Brien’ DC, et al. Financial burden of liver transplant vs resection for hepatocellular carcinoma. Transplant Proc. 2019;51:1907-12.
2. Rupp T, Zuckerman D. Quality of life, overall survival, and costs of cancer drugs approved based on surrogate endpoints. JAMA Intern Med. 2017;177:276-7.
3. Shahzad M, Naci H, Wagner AK. Estimated medicare spending on cancer drug indications with a confirmed lack of clinical benefit after US food and drug administration accelerated approval. JAMA Intern Med. 2021;181:1673-5.
4. US Department of Health and Human Services, Centers for Medicare and Medicaid Services. NHE Projections 2010-2020. Washington, DC: US Department of Health and Human Services. Available from: https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet. [Last accessed on 27 May 2026].
5. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76:681-93.
6. Iezzi R, Pompili M, Posa A, Coppola G, Gasbarrini A, Bonomo L. Combined locoregional treatment of patients with hepatocellular carcinoma: state of the art. World J Gastroenterol. 2016;22:1935-42.
7. Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current state of liver-directed therapies and combinatory approaches with systemic therapy in hepatocellular carcinoma (HCC). Cancers. 2019;11:1085.
9. Likhitsup A, Parikh ND. Economic implications of hepatocellular carcinoma surveillance and treatment: a guide for clinicians. Pharmacoeconomics. 2020;38:5-24.
10. Lai JC, Yang B, Lee HW, et al. Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease. Gut. 2025;74:2050-7.
11. Daher S, Massarwa M, Benson AA, Khoury T. Current and future treatment of hepatocellular carcinoma: an updated comprehensive review. J Clin Transl Hepatol. 2018;6:69-78.
13. Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol. 2021;75:960-74.
14. Moriguchi M, Kataoka S, Itoh Y. Evolution of systemic treatment for hepatocellular carcinoma: changing treatment strategies and concepts. Cancers. 2024;16:2387.
15. Kudo M, Aoki T, Ueshima K, et al. Achievement of complete response and drug-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study. Liver Cancer. 2023;12:321-38.
16. Singal AG, Yarchoan M, Yopp A, Sapisochin G, Pinato DJ, Pillai A. Neoadjuvant and adjuvant systemic therapy in HCC: current status and the future. Hepatol Commun. 2024;8:e0430.
17. Hasegawa K, Takemura N, Yamashita T, et al.; committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma, Tokyo, Japan. Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines). Hepatol Res. 2023;53:383-90.
18. Xie DY, Zhu K, Ren ZG, Zhou J, Fan J, Gao Q. A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2023;12:216-28.
19. Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82:315-74.
20. Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922-65.
21. Sukhera J. Narrative reviews: flexible, rigorous, and practical. J Grad Med Educ. 2022;14:414-7.
22. Jr PD, Fitzgerald SM. Using narrative literature reviews to build a scientific knowledge base. Work. 2001;16:165-70.
23. Horsley T. Tips for improving the writing and reporting quality of systematic, scoping, and narrative reviews. J Contin Educ Health Prof. 2019;39:54-7.
24. O’Brien B. Principles of economic evaluation for health care programs. J Rheumatol. 1995;22:1399-402.
25. Drummond MF, O’Brien BJ, Torrance GW, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Oxford University Press; 1997. Available from: https://shib.york.ac.uk/idp/profile/SAML2/POST/SSO?execution=e1s1. [Last accessed on 10 Jun 2026].
26. Saunders MN, Rojon C. On the attributes of a critical literature review. Coach Int J Theory Res Pract. 2011;4:156-62.
27. Doubilet P, Weinstein MC, McNeil BJ. Use and misuse of the term “cost effective” in medicine. N Engl J Med. 1986;314:253-6.
29. McIntosh E, Donaldson C, Ryan M. Recent advances in the methods of cost-benefit analysis in healthcare. Matching the art to the science. Pharmacoeconomics. 1999;15:357-67.
30. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
31. Husereau D, Drummond M, Petrou S, et al.; ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force. Consolidated health economic evaluation reporting standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16:231-50.
32. OANDA Corporation. Currency Converter. Available from: https://www.oanda.com/currency-converter/en/?from=EUR&to=USD&amount=1. [Last accessed on 27 May 2026].
33. Ye Z, Abduhilil R, Huang J, Sun L. Willingness to pay for one additional quality adjusted life year: a population based survey from China. Appl Health Econ Health Policy. 2022;20:893-904.
34. Chang TW, Chang WC, Chou WH, Chang WP, Kuo CN. Evaluating the cost-effectiveness of atezolizumab-bevacizumab in advanced hepatocellular carcinoma: Insights from Taiwan. J Food Drug Anal. 2025;33:163-71.
35. Liu L, Wang L, Ding Y, Zhang Q, Shu Y. Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study. BMJ Open. 2025;15:e094804.
36. Chee CE, Khara JS, Cheong J, et al. Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore. Expert Rev Pharmacoecon Outcomes Res. 2024;24:631-41.
37. Sriphoosanaphan S, Pantumongkol W, Kulpeng W, et al. Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand. PLoS One. 2024;19:e0300327.
38. Tseng CY, Tsai YW, Shiu MN. Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma. Front Oncol. 2023;13:1264417.
39. Gaugain L, Cawston H, Dubois de Gennes C, et al. Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France. PLoS One. 2023;18:e0280442.
40. Li Y, Liang X, Li H, Chen X. Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: a cost-effectiveness analysis. Cancer. 2022;128:3995-4003.
41. Zhang X, Wang J, Shi J, Jia X, Dang S, Wang W. Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib for patients with unresectable or metastatic hepatocellular carcinoma. JAMA Netw Open. 2021;4:e214846.
42. Chiang CL, Chan SK, Lee SF, Choi HC. First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis. Cancers. 2021;13:931.
43. Su D, Wu B, Shi L. Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma. JAMA Netw Open. 2021;4:e210037.
44. Wen F, Zheng H, Zhang P, Liao W, Zhou K, Li Q. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states. Liver Int. 2021;41:1097-104.
45. Xu Z, Ye ZM, Tang YK, et al. Cost-effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China. Cancer Med. 2023;12:14871-80.
46. Peng Y, Zeng X, Peng L, et al. Sintilimab plus bevacizumab biosimilar versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. Front Pharmacol. 2022;13:778505.
47. Zhou T, Wang X, Cao Y, et al. Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma. BMC Health Serv Res. 2022;22:1367.
48. Zhou T, Cao Y, Wang X, et al. Economic evaluation of sintilimab plus bevacizumab versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma. Adv Ther. 2022;39:2165-77.
49. Cheng S, Li B, Tang L, Liu S, Xiao J. Tremelimumab plus durvalumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the US payer perspective. BMJ Open. 2025;15:e090992.
50. Xiong X, Guo JJ. Cost effectiveness of tremelimumab plus durvalumab for unresectable hepatocellular carcinoma in the USA. Pharmacoeconomics. 2025;43:271-82.
51. Liao W, Xu H, Hutton D, et al. Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma. Ther Adv Med Oncol. 2024;16:17588359241274625.
52. Zhao Z, Jiang X, Wen S, Hao Y. Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China. Front Oncol. 2024;14:1491404.
53. Wei J, Xu K, Lin Y, et al. Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China. Int J Clin Pharm. 2024;46:1189-99.
54. Sun Y, Xu K, Yao H, et al. Cost-effectiveness of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a comparative analysis in China, the United States and Europe. Int J Clin Pharm. 2025;47:196-209.
55. Zheng Z, Lin Y, Cai H. Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis. Front Public Health. 2024;12:1356244.
56. Chen Q, Sun Q, Zhang J, Li B, Feng Q, Liu J. Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma. PLoS One. 2024;19:e0295090.
57. Shu Y, Tang Y, Ding Y, Zhang Q. Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma. Int Immunopharmacol. 2023;122:110543.
58. Li Y, Liang X, Li H, Yang T, Guo S, Chen X. Nivolumab versus sorafenib as first-line therapy for advanced hepatocellular carcinoma: a cost-effectiveness analysis. Front Pharmacol. 2022;13:906956.
59. Sherrow C, Attwood K, Zhou K, Mukherjee S, Iyer R, Fountzilas C. Sequencing systemic therapy pathways for advanced hepatocellular carcinoma: a cost effectiveness analysis. Liver Cancer. 2020;9:549-62.
60. Lian D, Gan Y, Xiao D, Xuan D, Liu S, Wei Y. Cost-effectiveness of first-line systemic therapies for unresectable hepatocellular carcinoma. Br J Clin Pharmacol. 2024;Epub ahead of print.
61. Wen F, Huang P, Wu Q, et al. Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. Cancer Med. 2024;13:e70094.
62. Sun KX, Cao SS, Shi FH, et al. First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States. Ther Adv Gastroenterol. 2022;15:17562848221140662.
63. Li L, Yang S, Chen Y, et al. Immune checkpoint inhibitors plus an anti-VEGF antibody as the first-line treatment for unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis. Front Pharmacol. 2022;13:891008.
64. Gong H, Ong SC, Li F, Weng Z, Zhao K, Jiang Z. Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China. Cost Eff Resour Alloc. 2023;21:20.
65. Wang L, Peng Y, Qin S, et al. First-line systemic treatment strategies for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. PLoS One. 2023;18:e0279786.
66. Guan H, Wang C, Zhao Z, Han S. Cost-effectiveness of donafenib as first-line treatment of unresectable hepatocellular carcinoma in China. Adv Ther. 2022;39:3334-46.
67. Zhao M, Pan X, Yin Y, et al. Cost-effectiveness analysis of five systemic treatments for unresectable hepatocellular carcinoma in China: an economic evaluation based on network meta-analysis. Front Public Health. 2022;10:869960.
68. Giuliani J, Mantoan B, Bonetti A. The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma. J Oncol Pharm Pract. 2022;28:434-7.
69. Meng R, Zhang X, Zhou T, Luo M, Qiu Y. Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma. Expert Rev Pharmacoecon Outcomes Res. 2022;22:1079-86.
70. Meyers BM, Vogel A, Marotta P, et al. The cost-effectiveness of lenvatinib in the treatment of advanced or unresectable hepatocellular carcinoma from a Canadian perspective. Can J Gastroenterol Hepatol. 2021;2021:8811018.
71. Ikeda S, Kudo M, Izumi N, et al. Cost-effectiveness of lenvatinib in the treatment of patients with unresectable hepatocellular carcinomas in Japan: an analysis using data from Japanese patients in the REFLECT trial. Value Health Reg Issues. 2021;24:82-9.
72. Saiyed M, Byrnes J, Srivastava T, Scuffham P, Downes M. Cost-effectiveness of lenvatinib compared with sorafenib for the first-line treatment of advanced hepatocellular carcinoma in Australia. Clin Drug Investig. 2020;40:1167-76.
73. Cai H, Zhang L, Li N, Zheng B, Liu M. Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. J Comp Eff Res. 2020;9:553-62.
74. Kim JJ, McFarlane T, Tully S, Wong WWL. Lenvatinib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma: a cost-utility analysis. Oncologist. 2020;25:e512-9.
75. Kobayashi M, Kudo M, Izumi N, et al. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. J Gastroenterol. 2019;54:558-70.
76. Sieg M, Hartmann M, Settmacher U, Arefian H. Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States. BMC Gastroenterol. 2020;20:120.
77. Shlomai A, Leshno M, Goldstein DA. Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis. Ther Adv Gastroenterol. 2019;12:1756284819878304.
78. Liao W, Huang J, Hutton D, et al. Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma. Liver Int. 2019;39:2408-16.
79. Soto-Perez-de-Celis E, Aguiar PN, Cordón ML, Chavarri-Guerra Y, Lopes GL. Cost-effectiveness of cabozantinib in the second-line treatment of advanced hepatocellular carcinoma. J Natl Compr Canc Netw. 2019;17:669-75.
80. Shlomai A, Leshno M, Goldstein DA. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis. PLoS One. 2018;13:e0207132.
81. Parikh ND, Singal AG, Hutton DW. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma. Cancer. 2017;123:3725-31.
82. Chiang CL, Chan SK, Lee SF, Wong IO, Choi HC. Cost-effectiveness of Pembrolizumab as a second-line therapy for hepatocellular carcinoma. JAMA Netw Open. 2021;4:e2033761.
83. Zheng H, Qin Z, Qiu X, Zhan M, Wen F, Xu T. Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with α-fetoprotein concentrations of at least 400 ng/ml. J Med Econ. 2020;23:347-52.
84. Gupta N, Verma RK, Prinja S, Dhiman RK. Cost-effectiveness of sorafenib for treatment of advanced hepatocellular carcinoma in India. J Clin Exp Hepatol. 2019;9:468-75.
85. Hamdy Elsisi G, Nada Y, Rashad N, Carapinha J. Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt. J Med Econ. 2019;22:163-8.
86. Parikh ND, Marshall VD, Singal AG, et al. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: an analysis of the SEER-Medicare database. Hepatology. 2017;65:122-33.
87. Zhang P, Yang Y, Wen F, et al. Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2015;27:853-9.
88. Gomersall JS, Jadotte YT, Xue Y, Lockwood S, Riddle D, Preda A. Conducting systematic reviews of economic evaluations. Int J Evid Based Healthc. 2015;13:170-8.
89. Adarkwah CC, van Gils PF, Hiligsmann M, Evers SM. Risk of bias in model-based economic evaluations: the ECOBIAS checklist. Expert Rev Pharmacoecon Outcomes Res. 2016;16:513-23.
90. Finn RS, Qin S, Ikeda M, et al.; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894-905.
91. Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23:77-90.
92. Ren Z, Xu J, Bai Y, et al.; ORIENT-32 study group. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 2021;22:977-90.
93. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163-73.
94. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1:EVIDoa2100070.
95. Qin S, Chan SL, Gu S, et al.; CARES-310 Study Group. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402:1133-46.
96. Qin S, Kudo M, Meyer T, et al. Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial. JAMA Oncol. 2023;9:1651-9.
98. Qin S, Bi F, Gu S, et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial. J Clin Oncol. 2021;39:3002-11.
99. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54-63.
100. Bruix J, Qin S, Merle P, et al.; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56-66.
101. Finn RS, Ryoo BY, Merle P, et al.; KEYNOTE-240 investigators. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38:193-202.
102. Zhu AX, Kang YK, Yen CJ, et al.; REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282-96.
103. Llovet JM, Ricci S, Mazzaferro V, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
104. Young KC, Kelly AG, Holloway RG. Reading a cost-effectiveness or decision analysis study: five things to consider. Neurol Clin Pract. 2013;3:413-20.
105. Zilberberg MD, Shorr AF. Understanding cost-effectiveness. Clin Microbiol Infect. 2010;16:1707-12.
106. Zhan Z, Chen B, Huang R, et al. Long-term trends and future projections of liver cancer burden in China from 1990 to 2030. Sci Rep. 2025;15:13120.
107. Sun J, Li Q, Bai X, et al.; Chinese Association of Liver Cancer and Chinese Medical Doctor Association. Chinese expert consensus on clinical application of molecularly targeted drugs for hepatocellular carcinoma (2022 edition). Chin Med J. 2024;137:2630-2.
108. Wilson BE, Booth CM. Real-world data: bridging the gap between clinical trials and practice. EClinicalMedicine. 2024;78:102915.
109. Chan LL, Kwong TT, Yau JCW, Chan SL. Treatment for hepatocellular carcinoma after immunotherapy. Ann Hepatol. 2025;30:101781.
